Fermenta Biotech Ltd. (FERMENTA) Share Price Falls 14.81% to Rs 467.25

Fermenta Biotech Ltd. fell to Rs 467.25, down 14.81% today, with market capitalisation at Rs 1,646.81 crore and turnover of Rs 7.08 crore.

Fermenta Biotech Share Price is in focus after the stock declined 14.81% today to Rs 467.25, compared with the previous close of Rs 548.50. At this price, the company’s market capitalisation stands at Rs 1,646.81 crore, placing it in the Small Cap bracket. The move is notable not only because of the magnitude of the single-session share price decline, but also because the supplied event flag confirms that the fall cleared the workflow’s qualifying bar for its market-cap category.

Trading data shows a sharp intraday swing. The stock opened at Rs 557.10, which was also the day’s high, and later fell to a low of Rs 441.45 before trading at Rs 467.25 at the event timestamp of 11 August 2026 at 2:17:06 PM IST. Total traded volume stood at 10,55,295 shares across exchanges, including 9,03,821 shares on NSE and 1,51,474 shares on BSE, while turnover on the reporting exchange was Rs 7.08 crore. That combination of a lower close versus the previous day and active volume participation has kept Fermenta Biotech Stock News among the more closely watched Stock Updates in today’s market session.

What is not established by the supplied data is a company-specific catalyst. In other words, the verified numbers confirm the price fall and explain why Fermenta Biotech Share Price Today is trending, but they do not identify a separate corporate trigger. For readers tracking Fermenta Biotech Latest News, Univest therefore focuses on what the market data, valuation ratios and sector benchmarks clearly show. The next questions are whether the stock’s Financial Analysis supports continued investor attention, how its profitability compares with peers, and where it sits inside the Healthcare and Pharmaceuticals & Drugs universe. That is the lens Univest uses in the sections below.

Fermenta Biotech Ltd. (FERMENTA) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 467.25
Previous Close	Rs 548.5
Today's Change	Rs -81.25 (-14.81%)
Day Open	Rs 557.1
Day High	Rs 557.1
Day Low	Rs 441.45
Current Volume (BSE)	1,51,474
BSE Traded Volume	1,51,474
NSE Traded Volume	9,03,821
Combined NSE + BSE Volume	10,55,295
Turnover	Rs 7.08 crore
Market Capitalisation	Rs 1,646.81 crore
Market Cap Category	Small Cap

Fermenta Biotech Ltd. (FERMENTA) traded at Rs 467.25. versus the previous close of Rs 548.5, a fall of 14.81%. The stock opened at Rs 557.1, reached Rs 557.1, touched Rs 441.45. Reported volume was 1,51,474.

Fermenta Biotech Ltd. (FERMENTA) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 1,646.81 crore
P/E Ratio	22.49x
P/B Ratio	4x
ROE	4.27%
ROCE	7.5%
EPS	Rs 24.38
Dividend Yield	0.68%

Fermenta Biotech Ltd. was valued at a P/E ratio of 22.49x, a P/B ratio of 4x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 4.27% and ROCE of 7.5%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 24.38, dividend yield of 0.68%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Fermenta Biotech Fundamental Analysis shows a company that is neither extremely expensive nor obviously cheap on supplied numbers alone, but one whose profitability profile appears softer than several sector benchmarks. The company’s market capitalisation is Rs 1,646.81 crore, which makes it much larger than the same-industry median market cap of Rs 146.99 crore and also above the industry average of Rs 500.01 crore across 137 companies. Size, however, should be separated from operating quality.

On valuation, the stock is trading at a P/E ratio of 22.49. Within the Pharmaceuticals & Drugs benchmark set, that is below the median P/E of 25.7 and far below the average of 69.27, although the average is influenced by a very wide range that runs from 3.08 to 3,396.3 across 104 companies with available P/E data. The P/B ratio stands at 4, which is above the benchmark median of 1.8 and above the average of 2.49. That suggests the market is still assigning a balance-sheet valuation premium relative to much of the same industry, even after today’s price fall.

Profitability metrics are more restrained. ROE is 4.27, below the industry median of 10.59 and the average of 8.24. ROCE is 7.5, also below the benchmark median of 12.98 and average of 15.72. These figures indicate that current returns on shareholder equity and capital employed are modest relative to a broad set of listed peers in the same industry. Fermenta Biotech Share Price therefore sits at an interesting intersection: valuation is not stretched on P/E versus the median, but profitability ratios do not yet match stronger sector performers.

EPS is Rs 24.38, which represents the earnings attributable to each share on the supplied data. Dividend yield is 0.68, giving investors a historical payout measure relative to the current market price, though not a future payout assurance. Taken together, the numbers show why Fermenta Biotech Stock Analysis requires nuance. Today’s decline has changed the price point, but the stock still needs to be read through both valuation multiples and operating return ratios. That naturally leads to the broader sector and industry context, where relative positioning becomes clearer. Univest views this balance between valuation and profitability as central to understanding the current Fermenta Biotech Stock News flow.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	22.49x
Benchmark Median P/E	25.7x
Benchmark Average P/E	69.27x
Benchmark P/E Range	3.08x to 3,396.3x
Company P/B Ratio	4x
Benchmark Median P/B	1.8x
Company ROE	4.27%
Benchmark Median ROE	10.59%
Company ROCE	7.5%
Benchmark Median ROCE	12.98%
Company Market Capitalisation	Rs 1,646.81 crore
Benchmark Median Market Cap	Rs 146.99 crore

Fermenta Biotech Ltd. (FERMENTA) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Fermenta Biotech Ltd. (FERMENTA) has a P/E ratio of 22.49x, which is below the benchmark median of 25.7x, a difference of -12.49%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Fermenta Biotech Ltd. (FERMENTA) has a ROE of 4.27%, which is below the benchmark median of 10.59%, a difference of -59.68%. Fermenta Biotech Ltd. (FERMENTA) has a ROCE of 7.5%, which is below the benchmark median of 12.98%, a difference of -42.22%.

Track today's top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.

Fermenta Biotech operates within the Healthcare sector and the Pharmaceuticals & Drugs industry, and the supplied benchmark covers 137 companies in that same industry. This context is important because today’s Fermenta Biotech Share Price Fall can be judged not only as an isolated price action event, but also relative to the valuation and profitability profile of its listed industry set.

The company’s P/E ratio of 22.49 sits below the benchmark median of 25.7 and well below the average of 69.27 across 104 companies with P/E data. On that measure alone, the stock is priced below the middle of the industry and far below the average, although the average is skewed by a very broad range between 3.08 and 3,396.3. By contrast, the company’s P/B ratio of 4 is higher than the benchmark median of 1.8 and higher than the average of 2.49 across 136 companies. That indicates the stock still trades at a richer book-value multiple than much of its industry cohort.

Return ratios present a tougher comparison. Fermenta Biotech’s ROE of 4.27 is below both the industry median of 10.59 and the average of 8.24. Its ROCE of 7.5 is also below the median of 12.98 and average of 15.72. So while the valuation on earnings appears relatively contained, the profitability profile is weaker than the broader same-industry benchmark. This mismatch matters in Financial Analysis because lower returns can limit how investors interpret a simple P/E discount.

Market capitalisation offers another lens. At Rs 1,646.81 crore, the company is substantially larger than both the benchmark median of Rs 146.99 crore and the average of Rs 500.01 crore, though still below the benchmark maximum of Rs 3,032.97 crore. For readers following Fermenta Biotech Market Cap and sector positioning on Univest, the data shows a company with above-average scale in its industry, a below-median P/E, an above-average P/B, and return ratios that trail sector norms. That combination helps explain why the stock can draw attention during bouts of Market Decline and weak Price Action.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	3,032.97	0	0.76	-2.89	-0.26
Hikal Ltd.	HIKAL	2,799.54	0	2.32	15.22	16.15
Kwality Pharmaceuticals Ltd.	KPL	2,707.2	40.09	9.77	28.21	26.35
Beta Drugs Ltd.	BETA	2,631.45	66.92	10.59	18.65	22.17
Panacea Biotec Ltd.	PANACEABIO	2,531.49	0	8.67	0	5.36

Fermenta Biotech Ltd. (FERMENTA) has a P/E ratio of 22.49x compared with the displayed peer median of 0x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 4.27% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 7.5% versus the displayed peer median of 16.15%, providing a capital-efficiency comparison. Fermenta Biotech Ltd. (FERMENTA) has a market capitalisation of Rs 1,646.81 crore. Among the 5 peers shown, 5 have a larger market capitalisation.

Fermenta Biotech’s peer set in Pharmaceuticals & Drugs provides a more concrete comparison than broad industry averages alone. With a market cap of Rs 1,646.81 crore, the company is smaller than all ten supplied peers, which range from Hester Biosciences Ltd. at Rs 2,057.85 crore to Dishman Carbogen Amcis Ltd. at Rs 3,032.97 crore. That places Fermenta in a lower size bracket within this particular comparison group even though it remains larger than the wider industry median.

On earnings valuation, Fermenta’s P/E of 22.49 is lower than Kwality Pharmaceuticals at 40.09, Beta Drugs at 66.92, Sai Parenteral’s at 181.97 and NGL Fine-Chem at 44.48. It is, however, higher than Venus Remedies at 17.49 and Hester Biosciences at 15.63 among peers where P/E is supplied. This suggests the stock sits in the lower-to-middle range of available peer earnings multiples rather than at an extreme discount or premium.

The P/B ratio of 4 is above Hikal’s 2.32, Solara’s 1.93, Sai Parenteral’s 3.36, Venus Remedies’ 2.96 and Dishman Carbogen’s 0.76, but below Kwality Pharmaceuticals’ 9.77, Beta Drugs’ 10.59, Panacea Biotec’s 8.67, NGL Fine-Chem’s 6.5 and Hester Biosciences’ 4.68. In other words, book-value valuation is elevated against some peers, but not the highest in the set.

Where Fermenta looks relatively weaker is profitability. Its ROE of 4.27 trails Hikal at 15.22, Kwality Pharmaceuticals at 28.21, Beta Drugs at 18.65, Sai Parenteral’s at 13.9, Solara at 17.23, NGL Fine-Chem at 27.9, Venus Remedies at 9.85 and Hester Biosciences at 16.17. Only Panacea Biotec at 0 and Dishman Carbogen at -2.89 are lower. ROCE tells a similar story: Fermenta’s 7.5 is below Hikal’s 16.15, Kwality’s 26.35, Beta’s 22.17, Sai Parenteral’s 12.97, Solara’s 15.34, NGL Fine-Chem’s 33.91 and Hester’s 14.12, while only Panacea’s 5.36 and Dishman’s -0.26 are lower. For investors reading Fermenta Biotech Stock Performance through peer data on Univest, the key takeaway is that the stock’s valuation is mixed, but profitability ranks in the lower part of the supplied peer range.

Why Investors Are Watching Fermenta Biotech

Fermenta Biotech Share Price is drawing attention because today’s 14.81% fall is large enough to put the stock among the session’s notable decliners, while the company’s valuation and profitability metrics create a mixed analytical picture. The price move is clear, volume participation is visible, and the stock’s sector and peer positioning give investors several concrete datapoints to monitor without turning the discussion into a recommendation.

• Verified price action: the stock fell Rs 81.25 to Rs 467.25 from Rs 548.50, after opening at Rs 557.10 and touching a low of Rs 441.45.
• Volume profile: total traded volume reached 10,55,295 shares across NSE and BSE, with Rs 7.08 crore turnover on the reporting exchange.
• Fundamental context: P/E is 22.49 and P/B is 4, while ROE at 4.27 and ROCE at 7.5 are below industry medians.
• Sector positioning: the company is larger than the same-industry median by market cap but trails many peers on profitability ratios.

What should investors monitor next? The most practical markers are whether Fermenta Biotech Share Price stabilises after today’s decline, how the stock trades relative to fresh volume participation, and whether valuation remains supported despite lower return ratios than many peers. Univest also sees the sector benchmark comparison as important, because the stock’s below-median P/E and above-average P/B create a balance that the market will continue to test.

About Fermenta Biotech

Fermenta Biotech Ltd. is part of the Healthcare sector and is classified within the Pharmaceuticals & Drugs industry. Even without a longer business description in the supplied dataset, this classification itself gives useful context for understanding the company’s market positioning. Businesses in this industry are generally evaluated through a combination of earnings multiples, book-value multiples, return ratios and relative scale, all of which are available here and help frame Fermenta Biotech Share Price in a sector-specific way.

On the supplied numbers, Fermenta Biotech is a mid-sized listed player within its immediate industry set by public-market standards, with a market capitalisation of Rs 1,646.81 crore. That is materially above the same-industry median market cap of Rs 146.99 crore and also above the average of Rs 500.01 crore across 137 benchmark companies. At the same time, the company remains smaller than each of the ten supplied peers used in the comparison set.

For readers following Fermenta Biotech Company News, the practical takeaway is that this is not a micro-scale listing with negligible market presence. It is a meaningful small-cap name inside the listed pharmaceuticals universe, and that is why its single-day price action can quickly attract attention on both NSE News and BSE News. The stock’s current analytical profile rests on three pillars visible in the data: reasonable relative earnings valuation, above-average book valuation, and profitability ratios that sit below many sector and peer benchmarks. That mix is central to any ongoing Fermenta Biotech Fundamental Analysis.

Track Fermenta Biotech Share Price on Univest

Use Fermenta Biotech Ltd. (FERMENTA) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.

Readers who want to follow Fermenta Biotech Share Price more closely can use Univest to monitor live Share Price movements, daily Stock Price changes and broader Market News context in one place. Fermenta Biotech Share Price Today can be tracked alongside core ratios such as P/E, P/B, ROE, ROCE, EPS and dividend yield, helping users compare price action with Financial Analysis rather than looking at the move in isolation.

Univest also helps investors track 52 Week levels, market capitalisation shifts, shareholding pattern updates when available, and sector-relative positioning across Healthcare and Pharmaceuticals & Drugs. For those searching Fermenta Biotech Share Price Live, Fermenta Biotech Stock News or Fermenta Biotech Share Price Update, the platform provides a structured way to watch price, volume and peer context as the story develops.

Frequently Asked Questions

Why is Fermenta Biotech Share Price falling today?

Ans. Fermenta Biotech Share Price fell 14.81% to Rs 467.25 from the previous close of Rs 548.50. The supplied data confirms the price event and active trading volumes, but it does not establish a company-specific catalyst for the decline.

What is Fermenta Biotech Share Price Today?

Ans. Fermenta Biotech Share Price Today is Rs 467.25 at the supplied event timestamp. The stock was down Rs 81.25 on the day, after opening at Rs 557.10 and moving within an intraday range of Rs 441.45 to Rs 557.10.

How much market capitalisation does Fermenta Biotech have?

Ans. Fermenta Biotech has a market capitalisation of Rs 1,646.81 crore. That places it in the Small Cap category and makes it larger than the same-industry median of Rs 146.99 crore in the supplied Healthcare benchmark dataset.

Was Fermenta Biotech among the top decliners today?

Ans. Yes, the supplied event flag shows the stock qualified under the price-fall threshold workflow for its Small Cap category. A 14.81% decline in one session also places Fermenta Biotech among notable top decliners in today’s market update.

What do today’s volume figures show for Fermenta Biotech?

Ans. Total traded volume in Fermenta Biotech stood at 10,55,295 shares, including 9,03,821 shares on NSE and 1,51,474 shares on BSE. Turnover on the reporting exchange was Rs 7.08 crore, indicating meaningful participation during the decline.

Is Fermenta Biotech expensive on P/E compared with its industry?

Ans. Fermenta Biotech trades at a P/E of 22.49, which is below the same-industry median of 25.7 and well below the average of 69.27. On earnings valuation alone, the stock appears below the middle of the benchmark set.

How does Fermenta Biotech compare on P/B ratio?

Ans. The company’s P/B ratio is 4, which is above the industry median of 1.8 and above the average of 2.49. So the stock trades at a richer book-value multiple than much of the supplied Pharmaceuticals & Drugs benchmark.

How strong are Fermenta Biotech’s profitability ratios?

Ans. Fermenta Biotech reports ROE of 4.27 and ROCE of 7.5. Both are below the industry medians of 10.59 and 12.98 respectively, suggesting profitability is weaker than the broader same-industry benchmark on supplied data.

What are the key per-share metrics for Fermenta Biotech?

Ans. Fermenta Biotech’s EPS is Rs 24.38 and its dividend yield is 0.68. EPS reflects earnings attributable to each share, while dividend yield shows the historical payout relative to the current stock price, not a future guarantee.

Which sector and industry does Fermenta Biotech belong to?

Ans. Fermenta Biotech belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied benchmark covers 137 companies in the same industry, which helps compare the stock’s valuation, market cap and profitability metrics.